FDA guidance questions histological endpoints in subset of NASH

FDA released draft guidance Thursday recommending clinical trials in NASH patients with compensated cirrhosis use a primary endpoint of time to complication, rather than histological improvement.

The guidance was one of two released by the agency on Thursday; the other focuses on expanding

Read the full 429 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE